American Society of Hematology

2017 ASH Meeting on Hematologic Malignancies

September 8-9, 2017
Fairmont Chicago, Millennium Park, Chicago, IL

Program Co-Chairs

Jonathan W. Friedberg, MD

Jonathan W. Friedberg, MD
University of Rochester

Ruben A. Mesa, MD

Ruben A. Mesa, MD
UT Health Cancer Center

Wendy Stock, MD

Wendy Stock, MD
The University of Chicago

Program Planning Committee

  • Anjali Advani, MD, Cleveland Clinic
  • Jonathan W. Friedberg, MD, University of Rochester
  • John P. Leonard, MD, Weill Cornell Medical College
  • Ruben A. Mesa, MD, UT Health Cancer Center
  • Vincent Rajkumar, MD, Mayo Clinic
  • David Steensma, MD, Dana-Farber Cancer Institute
  • Wendy Stock, MD, The University of Chicago

Corporate Support

ASH thanks the following for their support of this meeting:

  • AbbVie, Inc.
  • Agios Pharmaceuticals
  • Amgen, Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bristol-Myer Squibb
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co.
  • Novartis Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Pharmacyclics
  • Seattle Genetics
  • Takeda Oncology
  • Teva Oncology

Mobile app brought to you by Otsuka America Pharmaceuticals, Inc.

Exhibitors

  • AbbVie, Inc.
  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals
  • Celgene Corporation
  • Dana-Farber Institute
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Kite Pharma
  • Otsuka America Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Novartis
  • Takeda Oncology
  • Teva Oncology
back to top